TITLE

Research Capsules

PUB. DATE
January 2007
SOURCE
Pharmaceutical Representative;Jan2007, Vol. 37 Issue 1, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents news briefs related to the pharmaceutical industry in the United States as of January 1, 2007. Treatment with investigational drug Acomplia (rimonabant) can help improve cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes. The use of statins may slow damage to smokers' lungs. INSET: Actos.
ACCESSION #
23620466

 

Related Articles

  • Recent drug development for diabetes and obesity. Zammit, Victor // Primary Health Care;Jul2009, Vol. 19 Issue 6, p32 

    The article presents an overview of the expensive and complicated process that is used in the development of new drugs for diabetes and obesity. A discussion of drugs that have been developed for diabetes including metformin, and of drugs that have been developed for obesity including statins...

  • OTC statins: a step too far? Minhas, Rubin // GP: General Practitioner;6/16/2003, p41 

    The prospect of patients buying their own statins may be closer to becoming reality following calls by clinicians, including some from the ASCOT study group, for these drugs to be made available OTC. Recent trial data have given fresh impetus to calls to lower risk thresholds for CHD primary...

  • Statin Treatment in Diabetes Mellitus. Buse, John // Clinical Diabetes;Fall2003, Vol. 21 Issue 4, p168 

    Presents a study that examined the effectiveness of using hydroxymethylglutaryl-coenzyme A reductase inhibitors or statins in treating people with diabetes in Great Britain. Background on several marketed statins; Absorption, metabolism and adverse effects of statins; Clinical benefits of...

  • Follow up diabetes patients put on statins.  // Pulse;3/28/2012, Vol. 72 Issue 11, p9 

    The article reports on a Dutch research which reveals an over 70% risk of statin drug discontinuation by diabetic patients.

  • Accumulation of Cardiovascular and Diabetes Medication among Apparently Healthy Statin Initiators. Lavikainen, Piia; Korhonen, Maarit Jaana; Huupponen, Risto; Helin-Salmivaara, Arja // PLoS ONE;Feb2015, Vol. 10 Issue 2, p1 

    Purpose: To characterize accumulation of drug-modifiable cardiovascular (CV) risk factors in statin initiators who had no prior medication or hospitalizations for CV disease or diabetes. Methods: A cohort of 45-75-year-old statin initiators in Finland with no prior CV diseases, diabetes or...

  • Statin switch may not impact prescription market it. Johnsen, Michael // Drug Store News;1/17/2005, Vol. 27 Issue 1, p32 

    Reports on the impact of statin switch on the prescription market in the U.S. Marketing of Mevacor by Johnson & Johnson/Merck; Solicitation of physician guidance for treatment of hypercholesterolemia; Recommendation of effective prescription statin by physicians.

  • Statins could face generic threats.  // Drug Store News;1/17/2005, Vol. 27 Issue 1, p31 

    Reports on the impact of the Lipitor patent trial on operators in the prescription statin market in the U.S. Persistence of patent uncertainty through 2005; Increase in competition among generic drug manufacturers; Filing of patent infringement lawsuit by Pfizer.

  • Drug Sales, Spending Rise; Statins May Hit Stores Next. Bittar, Christine // Brandweek;6/21/2004, Vol. 45 Issue 25, pS61 

    Discusses the transition of prescription drugs to over-the-counter (OTC) status in the U.S. Potential conversion of cholesterol-fighting statins to OTC status in 2004; Sales performance of prescription drugs in 2003; Advertising campaigns launched by manufacturers of erectile dysfunction drugs.

  • The Promise of Phase 3. Zenger, Jack; Folkman, Joe; Sherwin, Robert // T+D;Jan2005, Vol. 59 Issue 1, p30 

    The article reports that modern medicine has enjoyed periodic breakthroughs of enormous significance. Sulfa drugs, penicillin, antibiotics, chemotherapy, CAT scans and the recent advent of statin drugs that lower blood pressure are examples of important pharmaceutical advances that transformed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics